RAD101 interim Phase 2b data - 92% achieve primary endpoint
Filed with ASX · · 3 pages · English
92% of evaluable patients at interim analysis treated with RAD 101 achieved concordance1 with MRI imaging (the primary endpoint) with significant and selective tumor uptake in suspected or recurrent brain metastases Company to host webinar on Tuesday, December 16 at 10:00 am AEDT (Australia) / Monday, December 15 at 6:00 pm EST (U.S.) Sydney, Australia– 15 December 2025 – Radiopharm Theranostics (
Radiopharm Theranostics Limited on 6ix
Earlier from Radiopharm Theranostics
- Amendment to Annual Report by Foreign Issuer (Form 20-F/A)
- Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer
- RAD Approval for Phase 1 Therapeutic Trial of RAD 402
- Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases
- RAD Announces 50% Enrollment in Phase 2b Trial of RAD101
Later from Radiopharm Theranostics
- Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases
- RAD Increases Ownership in Radiopharm Ventures to 87.5%
- Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live stream
- Presenting on Emerging Growth Conference 89 Day 2 on January 22; Register to live stream
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics